Hepatocellular carcinoma causes: Difference between revisions
Rabin Bista (talk | contribs) |
|||
| Line 17: | Line 17: | ||
[[Drospirenone and Ethinyl estradiol]], | [[Drospirenone and Ethinyl estradiol]], | ||
[[Fluoxymesterone]], | |||
[[Norethindrone acetate and Ethinyl estradiol]], | [[Norethindrone acetate and Ethinyl estradiol]], | ||
[[Norgestimate and Ethinyl estradiol]], | [[Norgestimate and Ethinyl estradiol]], | ||
Revision as of 19:11, 10 February 2015
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma causes On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma causes |
|
Risk calculators and risk factors for Hepatocellular carcinoma causes |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Causes
Acute and chronic hepatic porphyrias (acute intermittent porphyria, porphyria cutanea tarda, hereditary coproporphyria, variegate porphyria) and tyrosinemia type I are risk factors for hepatocellular carcinoma. The diagnosis of an acute hepatic porphyria (AIP, HCP, VP) should be sought in patients with hepatocellular carcinoma without typical risk factors of hepatitis B or C, alcoholic liver cirrhosis or hemochromatosis. Both active and latent genetic carriers of acute hepatic porphyrias are at risk for this cancer, although latent genetic carriers have developed the cancer at a later age than those with classic symptoms. Patients with acute hepatic porphyrias should be monitored for hepatocellular carcinoma.
Drug Side Effect
Drospirenone and Ethinyl estradiol, Fluoxymesterone, Norethindrone acetate and Ethinyl estradiol, Norgestimate and Ethinyl estradiol, Norgestrel and Ethinyl estradiol, Tamoxifen